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Epidemiological and economic burden of
Clostridium difficile in the United States:
estimates from a modeling approach
Kamal Desai1, Swati B. Gupta2,4*, Erik R. Dubberke3, Vimalanand S. Prabhu2, Chantelle Browne1
and T. Christopher Mast2

Abstract
Background: Despite a large increase in Clostridium difficile infection (CDI) severity, morbidity and mortality in the
US since the early 2000s, CDI burden estimates have had limited generalizability and comparability due to widely
varying clinical settings, populations, or study designs.
Methods: A decision-analytic model incorporating key input parameters important in CDI epidemiology was
developed to estimate the annual number of initial and recurrent CDI cases, attributable and all-cause deaths,
economic burden in the general population, and specific number of high-risk patients in different healthcare
settings and the community in the US. Economic burden was calculated adopting a societal perspective using a
bottom-up approach that identified healthcare resources consumed in the management of CDI.
Results: Annually, a total of 606,058 (439,237 initial and 166,821 recurrent) episodes of CDI were predicted in 2014:
34.3 % arose from community exposure. Over 44,500 CDI-attributable deaths in 2014 were estimated to occur.
High-risk susceptible individuals representing 5 % of the total hospital population accounted for 23 % of
hospitalized CDI patients. The economic cost of CDI was $5.4 billion ($4.7 billion (86.7 %) in healthcare settings;
$725 million (13.3 %) in the community), mostly due to hospitalization.
Conclusions: A modeling framework provides more comprehensive and detailed national-level estimates of CDI
cases, recurrences, deaths and cost in different patient groups than currently available from separate individual
studies. As new treatments for CDI are developed, this model can provide reliable estimates to better focus
healthcare resources to those specific age-groups, risk-groups, and care settings in the US where they are most
needed. (Trial Identifier ClinicaTrials.gov: NCT01241552)
Keywords: Cost, Community, Hospital, Long-term care, NAP1

Background
Clostridium difficile (C. difficile) is a gram positive,
spore-forming bacterium with sequelae ranging from
mild diarrhea to life-threatening pseudomembranous
colitis and even death [1, 2]. Persons at increased risk
for C. difficile infection (CDI) have advanced age, recent
antibiotic exposure, proton pump inhibitor use, long
length of stay in healthcare settings, serious underlying
illness, or immunocompromised conditions [3, 4].
* Correspondence: swati.gupta5@merck.com
2
Merck & Co., Inc., Kenilworth, NJ, USA
4
Merck & Co., Inc, 770 Sumneytown Pike, 19486 West Point, PA, USA
Full list of author information is available at the end of the article

Around 20 % to 30 % of patients will go on to have a
recurrent episode of CDI [5]. In addition to the aforementioned risk factors, prior recurrences and healthcare acquired infection further increase the
probability for subsequent recurrences [6, 7]. CDI
most commonly recurs within a week after treatment
cessation but can recur up to 6 to 8 weeks later.
A changing epidemiology of CDI in the United States
(US) and other industrialized countries has been
observed since the early 2000s resulting in a substantial
increase in the incidence and severity of CDI, especially
in patients over 65 years of age [6–9]. Hospitalizations
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with CDI as a principal diagnosis more than doubled in
the US from 33/100,000 population to 115/100,000
between 1993 and 2008 [10]. However, since 2009 a
levelling-off or decline of CDI incidence has been observed in the hospital setting [11], which may be attributable to increased awareness, leading to improved
environmental controls, hygiene or implementation of
more comprehensive prevention strategies. A recent
study reported an incidence of 48 and 93 per 100,000
population for community-associated and health careassociated infections, respectively in the US in 2011 [12].
These high incidence rates of disease may be due in part
to the emergence of a highly virulent strain of C.
difficile, known as restriction enzyme analysis type BI,
North American Pulsed Field type 1 (NAP1), or polymerase chain reaction ribotype 027. The BI/NAP1/027
strain has spread widely after first outbreaks in the eastern
US, Canada, and the United Kingdom [13]. While CDI is
well-recognized as an infection that is hospital-acquired,
recent studies have increasingly highlighted the importance of CDI in other settings such as the community or
long-term, outpatient care settings [1, 12, 14].
Estimates of epidemiological and economic burden of
CDI have relied on independent studies that vary
considerably in their designs, populations, and methodologies or have reported this burden secondary to other
objectives, making comparison and interpretation difficult [10, 12, 15–24]. One published source of CDI incidence in the US reports 336,600 hospitalizations in 2009
but does not include community-acquired cases or provide
estimates in higher risk groups [10]. Recurrence rates have
been variously reported between 3 % and 65 % (with most
estimates falling between 20 % and 30 %), depending on
period of observation, and risk factors such as episode, age,
strain, or other factors [3, 4, 10, 19, 21, 25, 26]. Mortality
estimates are similarly highly heterogeneous with estimates
ranging from 3 % to 36 % [4, 6, 8, 10, 19, 22, 26–33].
The uncertainty in such estimates makes it difficult to
understand the true CDI burden in the U.S. There is
limited information on CDI burden occurring in the
community, although more data are emerging in this
area, as is the evidence of burden in specific high-risk
patients, like the immunocompromised or organ transplant recipients. Economic burden estimates available
from multiple sources vary widely, capturing different
healthcare cost components in the management of CDI
or cost perspective [34–36]. There are limited estimates
of economic burden that include indirect costs such as
productivity losses.
Our objective was to obtain detailed estimates of the
epidemiological and comprehensive economic burden of
CDI in the US in 2014 using consistent methodology
across different risk groups, healthcare settings and
community.
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Methods
Model

We developed a decision-analytic model incorporating
CDI epidemiology, natural history and costs for patients
of different ages, and comorbid conditions from several
healthcare settings and the community for multiple
years, drawing primarily on published literature to
inform model parameters. Focusing on year 2014, the
model estimates the annual number of initial and recurrent CDI cases in the US by following the population of
susceptible patients in the US and simulating the natural
history of CDI from the index infection and up to six
recurrences in the subsequent 12 months. The model
also estimates severe episodes, colectomies, treatment
outcomes, deaths, and annual direct and indirect costs
for the population. The model was developed in Microsoft Excel (Version 14.0, 2010, Microsoft Corporation,
Redmond, WA).
Settings and patient population

We simulated the incidence of CDI in four settings: hospitals, long-term care facilities (LTC), long-term acute
care (LTAC) hospitals, and the community. Since this
study included modeled incidence of CDI, ethics review
was not required. Patients in each setting were stratified
into eight age groups: <1 year, 1–4 years, 5–9 years,
10–17 years, 18–44 years, 45–64 years, 65–84 years,
and 85+ years. The hospital population was further
divided into 5 groups at high risk for CDI: patients
with hematopoietic stem cell transplantation (HSCT),
inflammatory bowel disease (IBD), solid organ transplant (SOT), severe chronic kidney disease (CKD) and
immune-compromised patients, plus a sixth reference
group admitted to hospital not belonging to the
previous risk groups. More detail of settings and risk
groups is given in Additional file 1: Appendix A.
Natural history of CDI

The layout of the decision-analytic model is given in
Fig. 1 and follows the susceptible population for one
year. The model consists of chance nodes with associated probabilities that determine the proportion of the
population that is likely to follow a given natural history
pathway. From the initial chance node representing the
susceptible population, a proportion will experience incident CDI. Among these incident CDI cases, a certain
fraction is likely caused by NAP1/B1/027 versus other
strains. This strain dichotomization was chosen given
the epidemiologic importance of NAP1/BI/027 in terms
of mortality and recurrence. A proportion of persons
experience a severe episode (intensive care unit care,
colectomy or death attributable to CDI infection). Patients with the NAP1 strain have a higher chance of an
incident severe episode and death vs. patients with non-
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Fig. 1 Diagram of decision-analytic model of CDI showing natural history for a given age and risk group in a healthcare setting.
(*) Pathways for B, C, D are the same as for A, but downstream parameters for mortality and recurrence depend on strain. (**)
Pathway for second and subsequent recurrences follows the same natural history as first recurrence although the probability of
2nd + recurrence is greater than 1st

NAP1 strains. As CDI can be a recurrent disease, a proportion of patients cleared of the index infection experience a future episode. We assumed that recurrent
episodes were caused by the same strain as the initial
case. Survivors of the first recurrence may experience up
to five subsequent recurrences, where the probability of
the second recurrence and beyond is greater than the
first. Recurrence probabilities additionally depend on
strain and age [4, 10, 25].

Epidemiologic outcomes

The model generates epidemiologic outcomes for the
number of initial CDI cases, recurrent cases according
to order of the episode (first, second, third, fourth or
higher); number of severe CDI cases and deaths attributable to CDI and all-cause deaths. Outcomes are presented specific to age, risk group and healthcare setting
for year 2014.

Economic burden outcomes

Economic outcomes for primary and recurrent CDI included direct costs for hospitalization, pharmacotherapy,
healthcare professionals, and medical procedures, as well
as indirect costs due to productivity losses, number of
hospitalization days, and lost productivity. Costs were
estimated using a societal perspective; direct and indirect
costs for the hospital and community were included.
Direct costs were computed for primary and recurrent
cases. The quantities of each healthcare resource utilized
in the management of a case of CDI were identified
from the literature, and multiplied by unit costs of
each healthcare resource. The cost of a CDI episode
depended on its severity, whether it was primary or
recurrent, whether one or more courses of antibiotic
treatments were required and the patient’s age. Indirect costs included productivity losses associated with
inability to work and were estimated as a product of
national average age-specific wage rate, labor force
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participation, and duration of the episode. All cost
projections from the model were presented in 2014
US dollars.
Model parameters and data sources

Additional file 1: Appendix B gives key demographic,
epidemiologic and economic model parameters, their
base-case values and sources. Demographic parameters
specified the annual number of susceptible pools of individuals in the hospital, LTC, LTAC, and community settings. Epidemiological parameters included initial CDI
incidence, probability of incident cases due to NAP1/BI/
027 strain, case severity, mortality, and recurrence. Economic parameters specified costs and quantities of direct
and indirect costs associated with CDI.
Crude CDI incidence in the hospital setting combining
all age and risk groups was derived from an analysis of
primary and secondary diagnoses of CDI (ICD-9 008.45)
from the Healthcare Cost and Utilization Project
(HCUP) 2009 Nationwide Inpatient Sample [10]. In
order to avoid over-estimating episodes, we used HCUP
State Inpatient Databases (SID) [37] to estimate incidence of CDI as a primary or secondary diagnosis using
unique patient identifiers for the year 2010 amongst all
susceptible individuals; this analysis generated a correction factor that was applied to the 2009 data so that incidence rates were derived from individual patients that
were only counted once. Crude incidence in hospital
was also further adjusted downward to exclude 16.2 %
and 25.5 % of CDI cases that occur in LTC and community, respectively, who are transferred to hospital to further correct for any over counting of cases [22, 38].
In order to assign a relative risk of CDI incidence occurring in hospital to specific age- and risk-groups, we
separately utilized HCUP SID analyses using the same
International Statistical Classification of Diseases (ICD)
-9 codes which defined the susceptible individuals in the
hospital risk groups. In these separate analyses, patients
who belonged to HSCT, IBD, SOT, CKD, and immune
compromised were at 7.8, 4.1, 3.6, 4.5, and 4.9 times, respectively, greater risk of CDI (all ages combined) relative to crude CDI incidence (data not shown). We
excluded CDI infection in patients <1 year old since
cases in this age group typically represent colonization
rather than true disease. Similarly, we assumed HSCT is
unlikely to occur in individuals >85 years old; hence susceptible patients in this age and risk group were set to 0.
Incidence of CDI in LTC, LTAC and community
settings and other epidemiological parameters such as C.
difficile strain, severity, mortality, and recurrence were
based on the literature and assumptions described in Additional file 1: Appendix B. Additional file 1: Appendix B
also lists the healthcare resources consumed in the management of CDI cases, productivity losses, and their unit
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costs sources. In the base-case, non-severe cases of CDI
incurred on average 3 bed-days of hospitalization in the
general ward (GW) [30, 35, 39]. It was assumed that a severe case of CDI required 12 bed-days in the general ward
plus 11 bed-days in an ICU [39]. CDI cases managed in
the community assumed one general practitioner contact
per episode. Costs were also estimated for other procedures including colectomy, abdominal computerized axial
tomography (CT) scans, peripheral intravenous line insertion, endoscopy, and toxin tests. Further details are included in Additional file 1: Appendix B. Productivity
losses arising from CDI were calculated according to
the product of duration of the episode; the mean earnings by age of the patient, and labor participation by
age, obtained from the Bureau of Labor Statistics (BLS)
[40]. Cost inputs from years earlier than 2014 were
inflated using the CPI from BLS.
All CDI-related deaths were costed as severe CDI
cases, while non-CDI related deaths assumed costs of
non-severe CDI.
Base-case and sensitivity analysis

We presented the base-case results for estimated initial
and recurrent cases of CDI by setting, age, and risk factor in 2014. One-way sensitivity analyses were performed
by varying those parameters which were most influential
on the annual number of primary and recurrent CDI
cases and total economic cost of CDI. Further details are
provided in Additional file 1: Appendix C.

Results
Disease burden

In 2014, 606,058 episodes of CDI were expected nationwide in 439,237 patients who would subsequently have
166,821 recurrent episodes (see Table 1). A significant
number of CDI patients, 150,648 or 34.3 %, were estimated to have CDI from community exposure. There
were 112,152 (25.5 %) cases in LTC residents, and
170,229 (38.7 %) had overnight stays in an acute care
hospital. Less than 2 % of cases occurred in LTAC
settings.
High risk susceptible individuals (i.e., HSCT, IBD,
SOT, CKD, other immunocompromised patients) were
5 % of the total hospital population but accounted for
23 % of all CDI patients within hospital. Amongst the
355,780 patients with CKD, over 13,000 patients developed CDI, and burden was similar in patients who were
immune compromised. Between 1,600 and 6,900 patients from each of the remaining risk groups (HSCT,
IBD, and SOT) developed CDI. However, the majority of
patients developing CDI in hospital (131,114; 77.0 %)
were not associated with any of the five major risk
groups.

Hospital –
Ref Group

Hospital - HSCT

Hospital -IBD

Hospital -SOT

Hospital Immune
-Compromised

Hospital - CKD

Long Term Care

Long Term
Acute Care

Community

Total

No. of Susceptible Individuals

19,572,104
(6.13 %)

25,011
(0.01 %)

197,927
(0.06 %)

90,471
(0.03 %)

349,042
(0.11 %)

355,780
(0.11 %)

3,343,595
(1.05 %)

338,094
(0.11 %)

295,154,163
(92.40 %)

319,426,189
(100 %)

No. of Primary CDI cases

131,114
(29.85 %)

1,659
(0.38 %)

6,897
(1.57 %)

2,750
(0.63 %)

14,282
(3.25 %)

13,526
(3.08 %)

112,152
(25.53 %)

6,209
(1.41 %)

150,648
(34.30 %)

439,237
(100 %)

No. of Recurrent CDI Cases

65,664
(39.36 %)

644
(0.39 %)

3,128
(1.88 %)

1,190
(0.71 %)

6,843
(4.10 %)

6,730
(4.03 %)

61,247
(36.71 %)

3,064
(1.84 %)

18,311
(10.98 %)

166,821
(100 %)

1st recurrence

36,361
(37.56 %)

392
(0.40 %)

1,791
(1.85 %)

696
(0.72 %)

3,847
(3.97 %)

3,736
(3.86 %)

32,970
(34.06 %)

1,705
(1.76 %)

15,309
(15.81 %)

96,807
(100 %)

2nd recurrence

15,756
(41.17 %)

147
(0.38 %)

737
(1.93 %)

278
(0.73 %)

1,630
(4.26 %)

1,613
(4.21 %)

14,904
(38.94 %)

734
(1.92 %)

2,474
(6.46 %)

38,273
(100 %)

3rd recurrence

7,096
(42.49 %)

58
(0.35 %)

320
(1.92 %)

117
(0.70 %)

722
(4.32 %)

724
(4.34 %)

6,910
(41.38 %)

329
(1.97 %)

423
(2.53 %)

16,699
(100 %)

4+ recurrences

6,452
(42.88 %)

46
(0.31 %)

280
(1.86 %)

99
(0.66 %)

645
(4.29 %)

657
(4.37 %)

6,464
(42.96 %)

297
(1.97 %)

105
(0.70 %)

15,045
(100 %)

Severe CDI Cases (primary +
recurrent)

19,366
(32.59 %)

119
(0.20 %)

790
(1.33 %)

231
(0.39 %)

1,805
(3.04 %)

1,681
(2.83 %)

23,688
(39.86 %)

875
(1.47 %)

10,876
(18.30 %)

59,431
(100 %)

Deaths Attributable to CDI
(primary + recurrent)

14,525
(32.59 %)

89
(0.20 %)

592
(1.33 %)

173
(0.39 %)

1,353
(3.04 %)

1,261
(2.83 %)

17,766
(39.86 %)

656
(1.47 %)

8,157
(18.30 %)

44,572
(100 %)
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Table 1 Model-based estimates of CDI burden in the United States for 2014 by setting and risk group. Figures in parentheses are proportions of row totals
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Combining primary and all recurrent episodes, 13.5 %
of patients had severe CDI, and over 44,500 deaths
attributable to CDI were estimated to occur in 2014,
corresponding to a 10 % attributable CDI case-fatality.
Approximately one patient in four who was associated
with a healthcare setting having a primary case of CDI
had at least one further episode, but only 1 in 10 from
the community experienced a recurrence. Slightly fewer
than one-half of patients who experienced a first recurrent episode had a second recurrence, and about half of
those had a third recurrence. Recurrent cases by age are
given in the Additional file 1: Appendix C.
Combining all care settings, the greatest disease burden occurs in patients aged 65 years and over, representing 68.6 % of all CDI episodes, while 31.4 % of CDI
episodes occurred in those <64 years (Table 2). The majority of CDI cases occurring in patients up to age 44
were in the community. For patients over age 65 years,
the majority of CDI cases were found in the hospital or
LTC setting (Table 2).
Economic burden

Estimated economic costs of CDI in patients in the hospital, LTC, or LTAC were $4.7 billion dollars (86.7 %)
while the estimated cost of CDI in the community was
$725 million dollars (13.3 %), totaling $5.4 billion
(Table 3). Amongst all healthcare resource components,
overnight stays in the hospital contributed 78 % of the
total direct and indirect costs of CDI cases in healthcare
facilities and 52 % of costs for CDI cases originating in
the community (Table 3). Costs for pharmacotherapy,
healthcare professionals, surgery, and procedures were
each under 8 % as a share of total costs in healthcare facilities and under 15 % in the community. Productivity
losses associated with inability to work totaled $208 million (based on cases from all settings and initial and recurrent CDI episodes combined). The share of economic
burden attributed to either initial or recurrent CDI differed between healthcare facilities and the community.
In healthcare facilities, 67 % ($3.2 billion) of costs was
due to initial episodes and 33 % ($1.5 billion) was due to
recurrent episodes. For initial and recurrent costs, this
share was 89 % ($647 million) and 11 % ($77 million),
respectively, in the community (see Table 3).
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strain were also influential on total number of recurrent
cases. All-cause and attributable deaths were most sensitive to crude incidence of CDI and prevalence of NAP1/
BI/027 strain. By varying cost of hospitalization, annual costs of CDI ranged between $3.97 and $6.91
billion dollars in 2014.
Limitations

As with all models, there were a number of limitations
arising from data availability. As our model drew its parameter values from published literature, it was critical to
determine that the published data were based on suitable definitions and representative patients that matched
the model definitions. This can be problematic when the
model requires recurrence, mortality, and healthcare resource use to be conditioned on strain and severity of
the episode, a level of detail which is not generally available. This required a very careful selection of data or
combinations of data to run the model. Where values
from non-US studies were used, it was assumed that the
published estimate from Canada and Europe were based
on suitably comparable populations. However, a particular strength of the model is its use of HCUP SID data,
which permitted estimation of CDI incidence rates by
age and high risk groups for HSCT, IBD, SOT, CKD and
immune-compromised patients. The estimates of economic burden depended on assumptions surrounding
hospitalization cost and length of stay, which due to
their uncertainty, led to wide predicted ranges.
Structural and analytic choices were made as in all
modeling projects. In particular, our model used a dichotomization of C. difficile strain and a population
stratification that did not include sex and race, which
others have found to be important predictors of incidence in the United-States [12]. Another important analytic choice was the calculation of productivity loss that
depended on labour participation, which is generally low
in patients over 65 years of age who are most affected by
CDI. This choice has the effect of reducing the estimated
economic burden of CDI compared with estimating the
social value of non-workers and retirees as equal to the
employed population. Productivity losses for caregivers
of children and elderly, which may be important components of economic burden, were also not included due
to lack of data.

Sensitivity analysis

Additional file 1: Appendix C shows combined CDI burden estimates in all settings, age-, and risk-groups for
year 2014 under alternative parameter assumptions in
one-way sensitivity analyses. Cases of initial CDI were
most sensitive to crude incidence of CDI (range
351,389 – 527,084). Recurrent CDI was most sensitive
to recurrence rates (range 102,160–261,703), but probability of severe CDI and prevalence of NAP1/BI/027

Discussion
We developed a decision-analytic model in order to better understand the current and projected CDI burden in
the US. Our model allowed calculation of the number of
initial and recurrent CDI cases, and mortality rates by
age and risk groups and by setting of care. Previously
published studies have lacked comparability and this
level of granularity, thereby limiting clear interpretation
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Table 2 Model-based estimates of CDI burden in the United States for 2014 by setting and age. Figures in parentheses are proportion of row totals
1-4 Years

5-9 Years

10-17 Years

18-44 Years

45-64 Years

<64 Years

65-84 Years

≥ 85 Years

Total

Hospital

1,488 (0.58 %)

818 (0.32 %)

1,638 (0.64 %)

18,753 (7.37 %)

56,936 (22.38 %)

79,632 (31.30 %)

122,836 (48.28 %)

51,959 (20.42 %)

254,428 (100 %)

LTC

18 (0.01 %)

17 (0.01 %)

19 (0.01 %)

1,375 (0.79 %)

6,631(3.82 %)

8,059 (4.65 %)

81,857 (47.21 %)

83,482 (48.14 %)

173,399 (100 %)

LTAC

57 (0.61 %)

31 (0.33 %)

62 (0.67 %)

711 (7.67 %)

2,069 (22.31 %)

2,929 (31.58 %)

4,438 (47.85 %)

1,906 (20.55 %)

9,274 (100 %)

Community

2,900 (1.72 %)

3,631 (2.15 %)

6,000 (3.55 %)

34,126 (20.20 %)

52,982 (31.36 %)

99,639 (58.97 %)

59,845 (35.42 %)

9,475 (5.61 %)

168,959 (100 %)

Total

4,463 (0.74 %)

4,497 (0.74 %)

7,719 (1.27 %)

54,965 (9.07 %)

118,618 (19.57 %)

190,259 (31.39 %)

268,976 (44.38 %)

146,822 (24.23 %)

606,060 (100 %)
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Table 3 Economic burden of CDI in non-community (hospital, LTC, LTAC) and community settings in $USD. Figures in parentheses
are percentage of total costs
Non-community (Hospital, LTC, LTAC)

Direct Costs Due to CDI

Cost of Primary CDI Cases ($USD)

Cost of Recurrent CDI ($USD)

Total Cost, Primary and
Recurrent ($USD)

3,077,422,555(65.14 %)

1,515,321,696(32.07 %)

4,592,744,251(97.21 %)

Hospitalization Costs of Initial Cases

2,448,638,121(51.83 %)

1,228,876,113(26.01 %)

3,677,514,233(77.84 %)

Pharmacotherapy Costs of CDI Cases

182,348,058(3.86 %)

111,155,318(2.35 %)

293,503,376(6.21 %)

Healthcare Professional Costs of Initial Cases

271,079,343(5.74 %)

112,255,374(2.38 %)

383,334,717(8.11 %)

Surgical and Medical Procedure Costs

175,357,033(3.71 %)

63,034,891(1.33 %)

238,391,925(5.05 %)

Productivity Costs

92,848,421(1.97 %)

39,010,416(0.83 %)

131,858,837(2.79 %)

Cumulative number of hospital days

1,475,896(0.03 %)

801,821(0.02 %)

2,277,718(0.05 %)

Number of Lost Productivity Days

800,309(0.02 %)

348,256(0.01 %)

1,148,565(0.02 %)

Total Non-Community Cost

3,170,270,976(67.10 %)

1,554,332,112(32.90 %)

4,724,603,089(100.00 %)

Cost or Days of Primary
CDI($USD or days)

Cost or Days of Recurrent
CDI($USD or days)

Total, Primary and
Recurrent($USD or days)

Direct Costs Due to CDI

577,985,724(79.78 %)

69,767,755(9.63 %)

647,753,479(89.41 %)

Hospitalization Costs of Initial Cases

337,526,181(46.59 %)

43,205,334(5.96 %)

380,731,515(52.55 %)

Pharmacotherapy Costs of CDI Cases

92,088,119(12.71 %)

13,914,636(1.92 %)

106,002,754(14.63 %)

Healthcare Professional Costs of Initial cases

58,520,790(8.08 %)

5,214,073(0.72 %)

63,734,863(8.80 %)

Surgical and Medical Procedure Costs

89,850,635(12.40 %)

7,433,712(1.03 %)

97,284,347(13.43 %)

Indirect Costs Due to CDI

Community

Indirect Costs Due to CDI
Productivity Costs

69,351,125(9.57 %)

7,393,919(1.02 %)

76,745,044(10.59 %)

Cumulative Number of Hospital Days

197,951(0.03 %)

26,213(0.00 %)

224,163(0.03 %)

Number of Lost Productivity Days

602,020(0.08 %)

68,108(0.01 %)

670,128(0.09 %)

Total Community Cost

647,336,849(89.35 %)

77,161,674(10.65 %)

724,498,524(100.00 %)

Cost or Days of Primary
CDI($USD or days)

Cost or Days of Recurrent
CDI($USD or days)

Total, Primary and
Recurrent($USD or days)

Direct Costs Due to CDI

3,655,408,279(67.08 %)

1,585,089,451(29.09 %)

5,240,497,731(96.17 %)

Hospitalization Costs of Initial Cases

2,786,164,301(51.13 %)

1,272,081,447(23.34 %)

4,058,245,748(74.48 %)

Pharmacotherapy Costs of CDI Cases

274,436,177(5.04 %)

125,069,954(2.30 %)

399,506,131(7.33 %)

Healthcare Professional Costs of Initial cases

329,600,133(6.05 %)

117,469,447(2.16 %)

447,069,580(8.20 %)

Surgical and Medical Procedure Costs

265,207,668(4.87 %)

70,468,604(1.29 %)

335,676,272(6.16 %)

All settings

Indirect Costs Due to CDI
Productivity Costs

162,199,547(2.98 %)

46,404,335(0.85 %)

208,603,882(3.83 %)

Cumulative Number of Hospital Days

1,673,847(0.03 %)

828,034(0.02 %)

2,501,881(0.05 %)

Number of Lost Productivity Days

1,402,329(0.03 %)

416,364(0.01 %)

1,818,693(0.03 %)

Total Cost

3,817,607,826(70.06 %)

1,631,493,786(29.94 %)

5,449,101,612(100.00 %)

of true burden [10, 12, 15–24, 41]. Crude national
estimates of incidence or mortality have not considered the strain of C. difficile or provided burden in
specific patient populations with serious comorbid
conditions.

Our results agree with available estimates from US
CDI national surveillance [12]. Our model estimates that
in 2014, the absolute annual number of incident CDI
cases, when combining all healthcare settings and
community-based cases, was over 439,000 cases vs. the
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Centers for Disease Control and Infection (CDC) figure
of 453,000 cases in 2011 [12]. Our model estimates that
25.5 % of these cases originate within an LTC setting,
compared to 26 % estimated by CDC. Furthermore, our
model estimated that 34.2 % of CDI cases occurred in
the community which compares with their figure of
32 % of patients who were defined as community onset
and who did not have a hospital stay in the previous
12 weeks. Estimates of first recurrences were reasonably
similar: our model estimated 96,807 in 2014 compared
to the CDC figure of 83,000 in 2011. However, estimates
of deaths differed. Our model estimates that 44,572
deaths occurred in 2014 which is close to the upper limit
of CDC estimates of 29,300 (95 % CI, 16,500 – 42,100).
One reason explaining this difference is that our model
estimated up to 6 recurrences and hence more CDIattributable deaths were possible in our model, while
CDC figures estimated first recurrences only. It is interesting to note that CDI-attributable death estimates
from both our model-based estimates and those of CDC
exceed figures reported by the National Vital Statistics
Reports (NVSS) of 7,994 in 2011. One reason that may
explain the discrepancy with NVSS may be that the recorded cause of death in CDI patients with multiple comorbidities were attributed to other causes [42].
Previous estimates of the annual economic cost for
CDI in the US ranged from $436 million to $4.8 billion
(2008 US dollars) [34–36]. However, it has been suggested that these are low estimates because they do not
take into account factors such as outpatient costs, indirect costs, and decreases in productivity [36]. Our estimates, which factored these items, were accordingly
higher, indicating a total cost of $5.4 billion annually. In
our study, the main driver of costs was hospitalization,
accounting for between half to three-quarters of total
costs, depending on care setting. Up to one-third of total
costs were associated with recurrent CDI for patients
whose initial episode was associated with a healthcare facility, but this was much lower when the initial episode
was community acquired. Indirect costs were found to
be small relative to total economic burden, due to low
labor participation in the majority of CDI patients who
are over 65 years.

Conclusions
The results of the model described for this study are
useful for better identification of the settings and riskand age- groups in which CDI burden lies. Moreover,
these data permit a greater understanding of the burden
of recurrent episodes which has not been reported previously. Given the clinical challenges associated with the
of treatment of recurrent CDI and the improved recognition of CDI in high risk groups, these data provide
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insights into the potential value of emerging new treatment options that could benefit patients with CDI.
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